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Abstract Renal artery stensosis (RAS) continues to be a
problem for clinicians, with no clear consensus on how to
investigate and assess the clinical significance of stenotic
lesions and manage the findings. RAS caused by
fibromuscular dysplasia is probably commoner than previ-
ously appreciated, should be actively looked for in youn-
ger hypertensive patients and can be managed successfully
with angioplasty. Atheromatous RAS is associated with
increased incidence of cardiovascular events and increased
cardiovascular mortality, and is likely to be seen with
increasing frequency. Evidence from large clinical trials
has led clinicians away from recommending interventional
revascularisation towards aggressive medical management.
There is now interest in looking more closely at patient
selection for intervention, with focus on intervening only
in patients with the highest-risk presentations such as flash
pulmonary oedema, rapidly declining renal function and
severe resistant hypertension. The potential benefits in
terms of improving hard cardiovascular outcomes may
outweigh the risks of intervention in this group, and
further research is needed.
Keywords Renal artery stenosis . Atherosclerosis .
Fibromuscular dysplasia . Percutaneous transluminal renal
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Introduction
Renal artery stenosis (RAS) is defined as narrowing of main
or branch renal arteries and is most often caused by athero-
sclerotic disease or fibromuscular dysplasia (FMD). Notable
rarer causes include large vessel vasculitis (typically Takayasu
arteritis), renal artery aneurysm, extrinsic compression and
congenital malformations [1]. RAS may lead to the develop-
ment of renovascular disease and significant associated mor-
bidity in terms of hypertension and nephropathy. Atheroscle-
rotic RAS is also associated with adverse cardiovascular out-
comes. Despite extensive research in this area, the investiga-
tion, diagnosis and management of RAS remain controversial.
The clinical significance of RAS differs between patients, and
the indications for revascularisation are increasingly limited
when outcomes are compared with those of modern medical
management. This review will focus on the two main causes
of RAS, namely atherosclerosis and FMD, and will summa-
rise the latest evidence in this area, including the much
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anticipated results of the Cardiovascular Outcomes in Renal
Atherosclerotic Lesions (CORAL) study [2].
Atherosclerotic RAS
Atherosclerotic RAS typically affects the most proximal por-
tion of the renal artery, with build-up of atherosclerotic plaque
leading to narrowing of the arterial lumen. The reported
prevalence of atherosclerotic RAS differs widely, and athero-
sclerotic RAS is often found in high-risk patients with other
evidence of atheromatous disease. Approximately 20 % of
patients have bilateral disease or disease affecting a single
functioning kidney, but most patients have unilateral disease
[2, 3]. A general population of 870 participants in the Cardio-
vascular Health Study were screened using duplex ultraso-
nography, and the prevalence of RAS was 6.8 % with a mean
age of 78.7 years [4]. In high-risk populations the prevalence
can be significantly higher, with data from some centres
showing 18 % of patients undergoing coronary angiography
and 45 % of patients undergoing peripheral angiography have
evidence of RAS [5, 6].
Fibromuscular Dysplasia
FMD is recognised as the commonest cause of RAS after
atherosclerosis, and is thought to account for between 5 and
10 % of patients with renovascular disease. FMD is a non-
atherosclerotic, non-inflammatory vascular disease that can
affect any arterial bed, although it most commonly affects
the renal and carotid arteries [7]. FMD typically involves
medial and distal portions of the renal artery [8]. Classification
is based on findings on angiography and broadly divides FMD
into multifocal (mostly medial disease with the classic “string
of beads” appearance) and unifocal (single stenosis shorter
than 1 cm) or tubular (stenosis at least 1 cm in length) subtypes
[9]. Angiographic classification is important, as a recent sys-
tematic review found that patients with non-medial disease
had better blood pressure outcomes than patients with medial
disease after angioplasty [10]. The cause of FMD is unknown,
although around 10 % of cases are thought to be familial [11,
12]. Smoking is closely associated with FMD, but direct
causality has not been proven [13].
The prevalence of renal FMD is estimated at four per 1,000
population, although the true prevalence may be considerably
higher [7]. Screening investigations in potential renal donors
have found an FMD prevalence of 3.8 %, and a retrospective
cohort study of 2,640 living renal donors (of which 87%were
female with a mean age of 52 years) showed a prevalence of
2.6 % [14–16]. Only around one third of patients with inci-
dental FMD in these cohorts had a history of hypertension. A
US registry of FMD was commenced in 2008 and currently
has 447 recorded patients, of whom 294 have renal involve-
ment (the rest having predominantly carotid disease); the
mean age at diagnosis was 51.9 years, 91 % were female
and 72 % had a history of hypertension [12].
The Renovascular Syndrome
The potential clinical consequences of RAS include renovas-
cular hypertension and ischaemic nephropathy. The reduction
in renal perfusion attributable to RAS triggers a series of
hormonal and neuronal responses that raise systemic blood
pressure and therefore compensate for reduced renal blood
flow. This is seen most notably in activation of the renin–
angiotensin–aldosterone system (RAAS). Haemodynamic ef-
fects of stenotic lesions generally only become significant
when severe stenosis overcomes these compensatory mecha-
nisms, and this generally requires at least 80 % reduction in
the luminal diameter of the artery [17, 18].
Renovascular hypertension is the commonest secondary
cause of hypertension; however, essential hypertension still
accounts for approximately 95 % of hypertensive patients and
RAS will often be an incidental finding, particularly in older
patients. RAS is also often cited as a cause of renal function
decline and potentially end-stage renal disease. The UKRenal
Registry reports that 6.9 % of incident dialysis was due to
renovascular disease, and a 20-year follow-up of patients
starting dialysis in a single French centre found that 12 %
had documented evidence of RAS [19, 20]. It is not clear how
renovascular disease was diagnosed, and patients with a his-
tory of hypertension and declining renal function are often
labelled as having renovascular disease with limited or no
evidence of direct causality. Identification of an asymmetri-
cally small kidney in patients older than 50 years has a 70 %
chance of being due to significant atherosclerotic stenosis (but
it may be entirely asymptomatic) [11]. Flash pulmonary oe-
dema is also classically associated with bilateral RAS where
there is hypertension and extracellular fluid volume excess
due to impaired pressure natriuresis [21, 22]. RAS should be
suspected in patients with recurrent episodes of pulmonary
oedema, particularly if there is preserved left ventricular func-
tion on echocardiography.
The conditions that make up the renovascular syndrome
may be found alone or in combination, and all are multifacto-
rial; therefore, establishing a direct causal relationship with
RAS is often difficult. In an individual patient, the risk of
adverse outcomes due to RAS is dependent on the degree of
stenosis, the rate of progression and associated comorbidities,
none of which are easily defined or predictable. Significantly
increased cardiovascular mortality is associated with athero-
sclerotic RAS, and in one follow-up study of patients under-
going coronary angiography an incidental finding of renal
artery lesions was an independent risk factor for mortality,
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which approached 30 % at 4 years [23]. This is presumably
due to the high burden of atherosclerotic disease in these
patients.
Determining the likely progression of atherosclerotic le-
sions causing RAS is important when making management
decisions as progression to occlusion is not inevitable. A
prospective study of 295 kidneys in 170 patients found that
the cumulative incidence of progression was 51 % at 5 years,
and only nine patients underwent progression to complete
occlusion (significant risk factors for progression were greater
baseline stenosis, systolic hypertension and history of diabe-
tes) [24]. Another study found that over a 5-year follow-up
period, progressive narrowing of the stenotic diameter was
approximately 5 % per year and only around 50 % of arteries
showed progression [25]. Progression was not linear, but
occurred erratically and often rapidly, likely due to plaque
rupture or subintimal bleeding. There are very few data on
the progression of lesions in FMD; however, the risk of
hypertension increases with age, and there is some evidence
that the disease follows a more aggressive course in smokers
[7, 10, 13].
Which Patients Should Be Investigated for RAS?
Guidelines regarding who to investigate for atherosclerotic
RAS were published by the American College of
Cardiology/American Heart Association in 2005 and recom-
mend screening virtually all hypertensive patients, patients
with declining renal function, patients with discrepancy in
renal size and patients with sudden, unexplained pulmonary
oedema [22]. These guidelines predate a number of key clin-
ical trials which have substantially changed how atheroscle-
rotic RAS is managed. Current clinical consensus would
generally not advocate screening for atherosclerotic RAS in
everyone, particularly where it will not the alter management
plan. Suggested criteria for which patients to investigate are
outlined below:
1. Hypertension
– Rapid onset of hypertension over the age of 55 years
with additional adverse features (difficult-to-control
blood pressure, association with decline in renal
function, association with heart failure)
– Malignant, accelerated or drug-resistant hypertension
2. Deteriorating renal function
– Rapid, unexplained decline in renal function (more
than 50 % increase in serum creatinine concentration
over 12 months)
– Significant deterioration in renal function after intro-
duction of an ACE inhibitor or angiotensin II recep-
tor blocker
3. Repeated hospital admissions for heart failure with pre-
served left ventricular function on echocardiography
FMD expert consensus guidelines suggest that screening
for FMD should be undertaken in the investigation of hyper-
tension diagnosed before the age of 30 years, where there is
malignant (grade 3) hypertension, refractory hypertension
(hypertension despite triple-drug therapy including a diuretic)
or hypertension associated with a small kidney [22]. In view
of the mean age of patients diagnosed with FMD being over
50 years, it is also recommended that screening could be
considered in older hypertensive patients [7].
Investigation of RAS
The choice of investigation will depend on the clinical situa-
tion and local expertise. The gold standard investigation re-
mains catheter digital subtraction angiography as it provides
accurate anatomical information, an assessment of renal per-
fusion and the option of measuring the pressure gradient
across the stenotic region to provide information on the func-
tional significance of a demonstrated stenosis. With increasing
availability of high-specification imaging techniques, most
centres now use non-invasive imaging as the first-line inves-
tigation. Duplex ultrasonography is cheap and safe and is
particularly useful as a screening tool to exclude FMD in
patients with low probability of disease and in patients where
other forms of imaging are contraindicated (because of con-
cerns such as with contrast medium administration in patients
with renal impairment). A meta-analysis showed duplex ul-
trasonography has 85 % sensitivity and 82 % specificity for
detection of RAS [26], and estimation of the functional sever-
ity of the stenosis is possible byDoppler measurement of renal
artery velocity. Use may be limited in obese patients, and there
is potential for images to be obscured by bowel gas. The
results are also highly dependent on operator skill [7, 26,
27]. Comparisons of catheter angiography and duplex ultra-
sonography have found that ultrasound scans will generally
overestimate the degree of stenosis present [28]. Both
contrast-enhanced CT and MRI provide good anatomical
information, and the diagnostic sensitivity and specificity
have been shown to be 94 % and 93 % for CT angiography
and 90 % and 94 % for magnetic resonance angiography
[29–32]. A meta-analysis showed CT angiography and
gadolinium-enhanced magnetic resonance angiography gave
more accurate diagnoses than ultrasonography or captopril
scintigraphy [33]. CT angiography has higher spatial resolu-
tion than magnetic resonance angiography and is therefore
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probably a better tool for investigation of FMD [7]. For both
CT angiography and magnetic resonance angiography there
are concerns regarding use of contrast-enhanced studies, with
potential for contrast-medium-induced nephropathy after use
of non-ionic iodinated CT contrast media and nephrogenic
systemic fibrosis with some magnetic resonance gadolinium
chelate contrast media. Both are more likely in patients with
known renal impairment. As well as imaging the renal arteries
for occlusive disease, MRI may be used to quantitatively
assess renal perfusion using contrast-enhanced scans [34] or
arterial spin labeling [35, 36]. In addition, single-kidney renal
volumes may be derived from contrast-enhanced MRI which
correlate well with the single-kidney glomerular filtration rate
[37, 38]. Non-invasive imaging techniques have largely su-
perseded functional renal investigations or indirect tests for
RAS such as captopril renography, nuclear medicine reno-
grams or measurements of renal vein renin.
An emerging area of interest in the investigation of RAS is
use of blood-oxygen-level-dependent MRI. This non-invasive
technique does not require the use of a contrast medium and is
well validated as the basis for functional brain imaging tech-
niques. It is a method of estimating oxygenation of renal tissue.
A small pilot study of 23 kidneys showed 67 % sensitivity and
86 % specificity for detecting kidneys that were likely to
recover function after revascularisation [39]. This study
hypothesised that the ratio used in the calculations reflected
metabolically active hypoxic renal tissue that was potentially
salvageable following restoration of renal blood supply. Al-
though pilot studies have shown some promising results, there
are still inconsistencies in the data produced, and it is felt that
more experience of how to interpret the data from these scans is
required before they could be put into routine clinical use [40].
Management Overview
The management goals in RAS are to control hypertension,
preserve renal function and prevent recurrent flash pulmonary
oedema. Management of FMD is reasonably clear-cut; how-
ever, management of atherosclerotic RAS continues to be
debated, and it is apparent that there is no single strategy
suitable for all patients. The results of a number of key clinical
trials on the use of percutaneous transluminal renal artery
angioplasty (PTRAA) and significant improvements in med-
ical therapy have shifted the emphasis of management to-
wards conservative or medical care, and the role of
revascularisation is yet to be redefined.
Management of FMD
An expert consensus statement on management of FMD states
that revascularisation should be attempted only in those with
evidence of symptomatic disease (renovascular hypertension or
renal atrophy) [7]. One of the earliest renal angioplasty studies,
in 193 patients with FMD, showed a 50 % cure rate for
hypertension and the most recent cohort study showed a mean
blood pressure reduction of 17/7 mmHg after 12 months’
follow-up [41, 42]. A meta-analysis of 47 angioplasty studies
published in 2010 showed moderate benefit of angioplasty in
terms of hypertension, with a 36 % cure rate (defined as blood
pressure below 140/90 mmHg without medical therapy) [10].
Favourable outcome after angioplasty is predicted by younger
age (less than 40 years) at diagnosis, hypertension of less than
5 years’ duration and systolic blood pressure below 160 mmHg
[43]. There is no evidence that angioplasty for FMD improves
renal function. Long-term follow-up is important for patients
with an incidental finding of FMDas they are significantlymore
likely to develop hypertension over time (in one retrospective
cohort, 26.6 % of patients with FMD developed hypertension
over a 7.5-year follow-up period compared with 6.1 % of age-
matched controls) [15]. Therefore, although intervention may
not be appropriate at the first review, it may become appropriate
over time, and delay must be balanced against older patients
generally responding less well to intervention.
Medical Management—Atherosclerotic RAS
Current best medical management involves good blood pres-
sure control using antihypertensive medications, a statin, an
antiplatelet agent and lifestyle advice, particularly regarding
smoking cessation. Supporting evidence for blood pressure
control in the RAS patient group is extrapolated from general
populations with cardiovascular disease, chronic renal disease
and diabetes. RAAS antagonists (ACE inhibitors or
angiotensin II receptor blockers), calcium channel blockers
and beta blockers all have supporting evidence and general
acceptance for hypertension management in RAS. Historical-
ly, use of RAAS antagonists was contraindicated in this pa-
tient group owing to concerns of precipitating decline in renal
function. RAAS antagonists have been used as a screening
tool as patients who show a significant rise in creatinine
concentration after their introduction are likely to have evi-
dence of RAS (in a high-risk population, introduction of an
ACE inhibitor was 100 % sensitive and 70 % specific for
detection of severe bilateral RAS [44]). Concerns with RAAS
antagonists in this patient group are probably overstated, and
observational studies have shown improved outcomes using
this class of antihypertensive [11, 22]. In a prospective study
of 378 patients with renovascular disease, 92 % tolerated
introduction of RAAS antagonists and showed reduced mor-
tality [45]. A follow-up study of 195 patients with angiograph-
ic evidence of RAS found that those treated with RAAS
antagonists had improved survival whether or not a
revascularisation procedure was performed [46]. A further
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observational study of 3,570 Canadian patients with renovas-
cular disease found 53 % were taking RAAS antagonists and
these patients had significantly lower risk of death, myocardial
infarction or stroke [hazard ratio (HR) 0.70; 95 % confidence
interval (CI) 0.53–0.90] [47]. The concern with observational
data is that they reflect selection bias, and those able to tolerate
RAAS antagonists have less significant disease and would
have better outcomes anyway. Despite the lack of randomised
trials, there is a growing consensus that RAAS antagonists
should be used in patients with RAS but should be introduced
cautiously with careful monitoring.
Statin therapy has become a mainstay of treatment for all
atherosclerotic vascular disease [22]. Experimental models in
rats with RAS have shown that simvastatin reduces renal
fibrosis by upregulating antifibrogenic mediators and has
beneficial effects through antioxidant, anti-inflammatory and
antifibrotic actions [48]. These actions are seen in addition to
lowering of lipid concentrations, and may explain why statins
are so effective in treating cardiovascular disease. Observa-
tional data supporting statin therapy in RAS patients come
from a follow-up review of the data from the Single Operator,
Single Center, Renal Stent Retrospective Study (SOCRATES)
of 748 patients who underwent renal artery stenting which
found decreased mortality for those prescribed a statin (HR
0.69; 95 % CI 0.47–0.98) [49]. A retrospective study of 104
patients with atherosclerotic renal disease showed that over an
11-year follow-up period those receiving statin therapy had
significant reduction in renal end points (7.4% vs 38.9%) and
overall mortality (5.9 % vs 36.1 %) [50]. Cheung et al. [51]
showed that in 79 patients who had serial renal angiograms,
the risk of progression of RAS over a mean 28-month follow-
up period was reduced by statin therapy (relative risk 0.28;
95 % CI 0.10–0.77) and they postulated that statin therapy
could alter the natural history of atherosclerotic renovascular
disease. These results indicate that statins reducemortality and
limit lesion progression and should be considered in all pa-
tients with confirmed or suspected atherosclerotic RAS.
Use of antiplatelet agents and smoking cessation in patients
with atherosclerotic RAS has no specific supporting evidence,
but observational data looking at outcomes from other forms
of vascular disease, particularly peripheral vascular disease
and coronary disease, suggest that both strategies have merit,
and these results could be extrapolated to the RAS population
[52–56].
Atherosclerotic RAS Management—Revascularisation
Surgical revascularisation has largely been replaced by
PTRAA after trials in the early 1990s showed improved safety
with equal efficacy for balloon angioplasty compared with
surgical intervention [57]. Subsequent comparisons of angio-
plasty with and without stenting for atheromatous disease
showed increased long-term renal artery patency with use of
stents, and therefore stenting became a first-line treatment
[58–60]. Revascularisation of renal arteries with PTRAA be-
came extremely popular, and between 1996 and 2000 the
number of PTRAAs performed for RAS quadrupled in the
USA [61, 62]. The aim of revascularisation is to reduce ob-
struction to renal perfusion, thereby improving downstream
ischaemia and reducing activation of RAAS, resulting in im-
proved blood pressure control and preservation of renal func-
tion. The difficulty lies in knowing which patients will benefit
from revascularisation as a high degree of stenosis may not
correlate with significant haemodynamic effects and RASmay
be an incidental finding [63]. A number of randomised clinical
trials have now looked at outcomes for blood pressure, renal
function and cardiovascular mortality, comparing
revascularisation and bestmedical therapy against best medical
therapy alone. A summary of the most significant trials is
presented in Table 1, and the two largest trials, the Angioplasty
and Stenting for Renal Artery Lesions (ASTRAL) trial [3] and
CORAL trial [2] trial, are discussed further below.
Intervention with revascularisation is also not without risk,
and complications after PTRAA include haematoma at the
puncture site, renal injury due to contrast media, cholesterol
emboli and rarely renal artery dissection. One large case series
reported 30-day mortality after PTRAA of 2.2 % (all deaths
occurred in patients with atheromatous disease) [67]. In the
Stent Placement and Blood Pressure and Lipid-Lowering for
the Prevention of Progression of Renal Dysfunction Caused
by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR)
trial, there were two procedure-related deaths among 46 pa-
tients undergoing renal artery stenting [66].
Publication of the results from the ASTRAL trial [3] in
2009 played a pivotal role in discouraging clinicians from
recommending revascularisation, and the message from
ASTRAL trial has now been consolidated with the results
from the CORAL trial [2] published in 2013. ASTRAL
randomised 806 patients with evidence of renovascular dis-
ease and substantial anatomical atherosclerotic stenosis in at
least one renal artery. An additional inclusion criterion was
that the patient’s physician felt uncertain about the benefit of
revascularisation. Patients were randomised to receive either
medical treatment with a statin, an antiplatelet agent and
optimal blood pressure control or medical treatment with
revascularisation (either angioplasty alone or angioplasty
and stenting without the use of a renal protection device).
After 5 years’ follow-up, there were no significant improve-
ments in blood pressure or reductions in the incidence of renal
or cardiovascular events or mortality in the revascularisation
group, and the benefits in terms of renal function were not
clinically significant. There was also a procedure-related seri-
ous complication rate of 5 %. The investigators concluded that
there was some risk of harm and revascularisation did not
provide any benefit above that of medical therapy [3].
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CORAL [68] randomised 947 patients with atherosclerotic
RAS and either hypertension or chronic kidney disease to
receive optimal medical therapy [angiotensin II receptor
blocker (with or without thiazide with or without amlodipine),
an antiplatelet agent and atorvastatin] or optimal medical
therapy with revascularisation and stent placement (with use
of an embolic protection device at the operator’s discretion).
CORAL required demonstration of stenosis of more than
80 % by conventional CTor magnetic resonance angiography
or Doppler ultrasonography, or stenosis of 60-80 % with
evidence of a 20% pressure gradient across the stenotic lesion
on angiography. The CORAL inclusion criteria should have
selected patients with clinically significant stenosis; however,
mean stenosis in these patients was 68 % and only 39 % of
patients had stenosis of more than 80% (whichmay have been
overestimated depending on the imaging technique used).
After a median 43-month follow-up period there was no
difference between the groups for the primary composite end
point (cardiovascular and renal adverse events), for the indi-
vidual components of the end point or for all-cause mortality.
The degree of stenosis at screening did not influence the
outcomes. There was a statistically significant difference of
around 2 mmHg in favour of the stent group for systolic blood
pressure control. Eleven patients (2.4 %) in the stent group
had a serious complication in the form of renal artery dissec-
tion. The CORAL investigators similarly concluded that there
was no benefit to patients from revascularisation and there
was some risk of harm.
The use of revascularisation in management of flash pul-
monary oedema is supported by some evidence from older
case series [69, 70]. In one series of patients with proven RAS,
41 % of patients with bilateral disease had a history of pulmo-
nary oedema, and following stenting, 77 % of these patients
had no further episodes of pulmonary oedema [71]. A recent
systematic review included data from 173 patients and con-
cluded that the quality of evidence was low and justified only a
weak recommendation for PTRAAwith or without stenting in
patients with atherosclerotic RAS and either flash pulmonary
oedema or chronic heart failure and renal insufficiency [72].
The interpretation of the results of the large trials so far in
the management of atherosclerotic RAS has been limited by
patient selection and methodological issues including cross-
over from medical to intervention arms and analysis based on
intention to treat (when not all randomised patients actually
underwent a procedure). ASTRAL was criticised for includ-
ing patients who would never normally have been considered
for revascularisation, i.e. patients for whom there was insuffi-
cient clinical evidence that the degree of stenosis identified
was causing significant adverse outcomes and who, therefore,
would never be expected to benefit from such a procedure.
CORAL, although more robust in its patient selection, still
included patients with stable disease and has similarly been
criticised as proving only that treating non-significant lesions
does not significantly change outcomes.
The Future of Revascularisation in RAS
The concern now is that the entire idea of revascularisation
will be discarded when actually what is needed is a new
Table 1 Summary of randomised controlled trials for revascularisation versusmedical therapy in the management of atherosclerotic renal artery stenosis
(RAS)
Study Population Intervention Findings Reference
Scottish and Newcastle
Renal Artery Stenosis
Collaborative Group
(1998)
135 participants, >40 years,
hypertension, RAS >50 %
PTRAA and medical therapy
vs medical therapy alone
Significant fall in BP after PTRAA
in bilateral RAS only
[64]
Dutch Renal Artery
Stenosis Intervention
Study Group (2000)
106 participants, hypertension,
RAS >50 %
PTRAA and medical therapy
vs medical therapy alone
No difference in BP or renal function
outcomes between groups
[65]
STAR (2009) 140 participants, CrCl <80
ml/min, RAS >50 %
PTRAAwith stenting and medical
therapy vs medical therapy
alone
Stent placement had no impact on renal
function. Significant complications
with procedures
[66]
ASTRAL (2009) 806 participants, RAS >60 %,
uncertainty as to benefit of
revascularisation
PTRAAwith or without stenting
and medical therapy vs medical
therapy alone
No difference in BP, renal function
or mortality between groups
[3]
CORAL (2013) 947 participants, hypertension
and CKD, RAS >80 %
(or 60–80 % with pressure
gradient)
PTRAAwith stenting and medical
therapy vs medical therapy
alone
No difference in incidence of CVand
renal events or all-cause mortality.
2-mmHg improvement in systolic
BP in stent group
[2]
ASTRAL Angioplasty and Stenting for Renal Artery Lesions, BP blood pressure, CKD chronic kidney disease, CORAL Cardiovascular Outcomes in
Renal Atherosclerotic Lesions, CrCl creatinine clearance, CV cardiovascular, PTRAA percutaneous transluminal renal artery angioplasty, STAR Stent
Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of
the Renal Artery
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perspective on patient selection. Case reports and case series
have shown that there is a group of patients who appear to
benefit from revascularisation; however, at present we have no
method of reliably preselecting these patients. Radiological
estimations of the degree of stenosis are unreliable and corre-
late poorly with outcomes, rate of progression of stenosis is
unpredictable and biomarkers such as renin and B-type natri-
uretic peptide are not specific or sensitive enough [73–75].
Future decisions on revascularisation are likely to be made on
an individual patient basis, with clinical presentation as the
key determinant for the management strategy adopted.
Revascularisation is not a risk-free procedure; therefore, it
is likely that only patients perceived to be at high risk of an
adverse outcome owing to RAS will be considered for inter-
vention. A retrospective analysis of a patient cohort from a
single UK centre looked at patients with the highest-risk
presentations of RAS (flash pulmonary oedema, rapidly de-
clining renal function, refractory hypertension) and compared
the outcomes for both medical therapy and revascularisation
in these patients with those for low-risk patients (those who
had none of the above-mentioned features). In total, 467
patients were included, of whom 51 % had at least one high-
risk feature. After a median 3.8-year follow-up period, pa-
tients presenting with flash pulmonary oedema had a signifi-
cantly higher incidence of cardiovascular events and death;
however, this risk was reduced if these patients underwent
revascularisation (HR 0.43; 95 % CI 0.20.9). There were also
non-significant trends towards improved outcomes in patients
presenting with two or more high-risk features. The study
authors acknowledged the limitations of their study using
observational data and small patient numbers, but concluded
that patients with flash pulmonary oedema and patients with
more than one high-risk feature at presentation should be
considered for revascularisation and further clinical trials in
these high-risk groups were necessary [76].
Conclusion
RAS secondary to FMD is probably commoner than previously
thought. FMD should be actively looked for in young (partic-
ularly female) patients presenting with hypertension and should
be considered in older patients with difficult-to-treat hyperten-
sion. Management with angioplasty is recommended in symp-
tomatic patients, and outcomes are generally good, particularly
in younger patients. RAS secondary to atherosclerosis is likely
to be seen with increasing frequency owing to an aging popu-
lation undergoing more imaging studies. Current best evidence
supports aggressive medical management in these patients with
good blood pressure control (including use of an RAAS antag-
onist) and a statin. Less evidence-based but probably reason-
able additional treatment would be an antiplatelet agent and
lifestyle advice. Revascularisation may be considered for a
subset of patients who fail to stabilise with medical manage-
ment or for patients who present with multiple high-risk fea-
tures, particularly flash pulmonary oedema. Reliable, objective
criteria for identifying patients who will benefit from
revascularisation have yet to be established, and prospective
trials in these subsets of patients are now needed.
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